Nipent (Pentostatin)

Pentostatin, the active ingredient in Nipent, is an antimetabolite presented as an intravenous solution for infusion use. It is employed in the treatment of certain hematologic malignancies, notably chronic lymphocytic leukemia and hairy cell leukemia, by targeting malignant lymphocytes.

GNH USA supplies Nipent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide. The company provides regulatory‑approved product quality and reliable cold‑chain logistics to meet global clinical demand. Clients benefit from GNH USA's extensive experience in oncology drug distribution across Europe, Asia and the Americas.

Pentostatin is an antimetabolite chemotherapy agent used primarily in hematologic oncology to treat specific lymphoid cancers where it targets malignant lymphocytes. - Chronic lymphocytic leukemia: Pentostatin is administered to patients with CLL to decrease leukemic cell proliferation, improve blood counts, and prolong progression‑free survival as part of combination regimens. - Hairy cell leukemia: Pentostatin is employed to induce durable remissions by targeting the abnormal B‑cell clone, often leading to normalization of marrow function and reduction of splenomegaly.

Pentostatin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach often occurring during or after infusion. - Fatigue: persistent tiredness that may affect daily activities. - Low white blood cell count (neutropenia): reduced neutrophils increasing infection risk.

Serious or Rare Side Effects: - Severe infections due to immunosuppression: opportunistic bacterial, fungal or viral infections that may be life‑threatening. - Acute respiratory distress syndrome: rapid onset breathing difficulty requiring intensive care. - Renal failure: impaired kidney function that may necessitate dialysis.

When using Pentostatin, clinicians should observe specific safety measures to minimize risks. - Monitor blood counts: perform complete blood count before each dose and regularly during therapy. - Assess liver and kidney function: evaluate hepatic enzymes and renal parameters prior to treatment. - Use anti‑emetic prophylaxis: consider medications to prevent nausea and vomiting associated with infusion. - Avoid concurrent myelosuppressive agents: limit use of other drugs that further lower blood cell production. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Pentostatin can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: increased risk of severe infection; avoid administration during treatment. - Strong immunosuppressants (e.g., high‑dose steroids): may exacerbate myelosuppression.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may increase Pentostatin plasma levels. - Allopurinol: can enhance toxicity by affecting purine metabolism. - NSAIDs: may worsen renal impairment when combined.